8-K
filed October 19, 2023, 7:59 PM ET
ticker TECH
CIK 0000842023
leadership
confidence high
sentiment neutral
materiality 0.75
Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024
BIO-TECHNE Corp
- Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.
- CEO salary set at $900,000 base (COO $750,000), target bonus 110% (COO 100%); equity grants valued at $6.2M total.
- Kelderman has led Diagnostics & Genomics since 2018; previously executive at Thermo Fisher and BD.
- Retention RSUs awarded to candidates Geist (~$1.05M) and Hippel (~$1.39M) vesting over two years.
- Kummeth tenure: revenue grew from $311M to $1.1B, 19 acquisitions, headcount from 800 to 3,200.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kim Kelderman was appointed as Chief Executive Officer at BIO-TECHNE Corp.
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kim Kelderman was appointed as Chief Operating Officer at BIO-TECHNE Corp.
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Chuck Kummeth retired as Director at BIO-TECHNE Corp.
- Action
- retired
- Role
- Director
Exact text from the filing
Mr. Kummeth will also retire from the Board of Directors on such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Chuck Kummeth was appointed as Senior Advisor at BIO-TECHNE Corp.
- Action
- appointed
- Role
- Senior Advisor
Exact text from the filing
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kim Kelderman was appointed as Director at BIO-TECHNE Corp.
- Action
- appointed
- Role
- Director
Exact text from the filing
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Chuck Kummeth retired as Chief Executive Officer at BIO-TECHNE Corp.
- Action
- retired
- Role
- Chief Executive Officer
Exact text from the filing
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.